Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ResMed Inc. filings document operating results, governance actions, capital returns and securities registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and fiscal-year financial results, record board-declared cash dividends and describe the treatment of NYSE common stock and ASX CHESS Depositary Interests in dividend payments.
The company’s regulatory record also covers board composition, director elections, executive officer transitions, compensation arrangements and amendments to the ResMed Inc. 2009 Incentive Award Plan. Proxy materials provide stockholder voting matters, executive compensation disclosure and corporate-governance information for the medical technology company’s public-company structure.
ResMed Inc Chairman and CEO Michael J. Farrell exercised stock options and sold shares in a pre-planned transaction. He exercised options for 4,991 shares of ResMed common stock at an exercise price of $146.3400 per share, then sold 4,991 shares in open-market trades at a weighted average price of $218.5475 per share.
The sales were executed in multiple trades at prices ranging from $216.772 to $219.700 under a Rule 10b5-1 plan adopted on October 31, 2024. Following the transactions, Farrell directly holds 466,223 shares of ResMed common stock and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust, and 19,966 stock options remain outstanding.
ResMed is reshaping its portfolio by agreeing to sell its MatrixCare software business to Frazier Healthcare Partners for $490 million in cash, with closing expected in the first quarter of fiscal 2027, subject to regulatory approvals and customary conditions. MatrixCare generated about $220 million of revenue and $55 million of non-GAAP operating profit in fiscal 2026.
ResMed plans to use net proceeds to return capital to shareholders, including via an accelerated share repurchase program, and for general corporate purposes. Transition services agreements are expected to largely offset first-year stranded costs. The company also notes its Noctrix acquisition should add roughly $30 million of revenue in fiscal 2027 but reduce non-GAAP diluted EPS by about $0.20, while it reiterates its fiscal 2026 outlook and targets high single-digit revenue growth with operating leverage in its Residential Care Software segment in fiscal 2027.
Michael Farrell submitted a Rule 144 notice to sell 4,991 shares of Common Stock on 07/07/2026 via a stock option exercise to be settled for cash. The filing also lists three prior sales of 4,991 shares each on 04/07/2026, 05/07/2026, and 06/08/2026 with proceeds shown in the excerpt.
RESMED INC Chairman and CEO Michael J. Farrell reported an exercise-and-sale transaction in company stock. On June 8, 2026, he exercised options to acquire 4,991 shares of ResMed Common Stock at $146.34 per share and sold the same 4,991 shares in open-market trades at a $193.962 weighted average price. The sales were executed in multiple trades between $192.605 and $194.715 under a pre-arranged Rule 10b5-1 plan adopted October 31, 2024. Following these transactions, he directly held 466,256 ResMed shares, with 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust and 24,957 stock options remaining outstanding.
RMD reported a Form 144 notice for the sale of 4,991 shares of Common Stock via a stock option exercise on 06/08/2026. The filing lists three prior monthly dispositions of 4,991 shares each on 03/09/2026, 04/07/2026, and 05/07/2026 with cash proceeds shown.
ResMed Inc Global General Counsel Michael J. Rider reported a small tax-related share disposition. On June 1, 2026, 268.742 shares of ResMed common stock were surrendered at $190.57 per share to cover tax withholding on the vesting of Restricted Stock Units that were granted on June 1, 2023. This was a tax-withholding mechanism, not an open-market sale. After this transaction, Rider directly holds 9,488 shares of ResMed common stock, which includes 66.0288 shares purchased on April 30, 2026 through the ResMed Employee Stock Purchase Plan.
Issuer filed a Form 144 reporting proposed resale and recent dispositions of common stock. The filing lists 8,000 shares associated with Fidelity Brokerage Services LLC with an aggregate value of $1,672,560.00 and two disclosed past sales by Brett Sandercock of 1,000 shares on 03/02/2026 for $254,300.00 and 1,000 shares on 04/01/2026 for $224,310.00. The securities are noted as from Restricted Stock Vesting dated 11/21/2019.
ResMed Inc.’s Chairman and CEO Michael J. Farrell reported a same-day option exercise and share sale in ResMed common stock. He exercised options to acquire 4,991 shares at $146.34 per share, then sold 4,991 shares in an open-market transaction at a weighted average price of $207.8206 per share.
After the sale, Farrell directly holds 466,223 ResMed shares and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust. The transactions were conducted on May 7, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2024, indicating a scheduled, routine disposition rather than ad hoc trading.
Michael Farrell reported a proposed sale of 4,991 shares of Common Stock under Rule 144 on 05/07/2026. The form lists an option granted dated 11/21/2019 and shows three prior sales of 4,991 shares on 02/09/2026, 03/09/2026, and 04/07/2026 with dollar figures provided alongside each sale.
RESMED INC executive Aaron Bloomer, the company’s Chief Financial Officer, filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting insider of ResMed but does not list any equity holdings or report any buy or sell transactions.